Table 3.

ACIP recommendations for meningococcal ACWY and meningococcal B vaccines in children and adults with asplenia or hyposplenia^{33,34,37,38,51}

Age at first dose	Timing of first dose of meningococcal vaccine	Total doses of meningococcal vaccine	Interval between meningococcal vaccines	Revaccination
MenACWY-CRM (MENVEO)
8 wk	—	4-dose series	2-mo, 2-mo, 6-mo intervals	Revaccinate 3 y after primary series; additional boosters every 5 y if risk remains
7-23 mo	—	2-dose series	12-wk interval and second dose at ≥12 mo of age	Revaccinate 3 y after primary series; additional boosters every 5 y if risk remains
≥24 mo	—	2-dose series	8-wk interval	Revaccinate 3 y after primary series if most recent dose given before age 7 y; additional boosters every 5 y if risk remains
MenACWY-D (Menactra)
9-23 mo	Do not administer, because of immune interference with PCV13
≥24 mo	Administer >4 wk after completion of PCV13 series	2-dose series	8-wk interval	Revaccinate 3 y after primary series; additional boosters every 5 y if risk remains
MenB-4C (BEXSERO)*
≥10 y	—	2-dose series	1-mo interval	Revaccinate 1 y after primary series and revaccinate every 2-3 y if risk remains†
MenB-FHbp (Trumenba)*
≥10 y	—	3-dose series	1-mo, 4-mo intervals	Revaccinate 1 y after primary series and revaccinate every 2-3 y if risk remains†

^*Use same product for all doses in a series

†MenB booster doses now recommended for person ≥ 10 y with asplenia as of June 2019.